argenx (NASDAQ:ARGX – Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership. Institutional & Insider Ownership 52.8% of argenx shares are […]
Wrapmanager Inc. purchased a new stake in argenx SE (NASDAQ:ARGX – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 435 shares of the company’s stock, valued at approximately $214,000. Several other hedge funds and other institutional investors have […]
Assenagon Asset Management S.A. raised its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 40.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,326 shares of the company’s stock after purchasing an additional 11,257 shares during the quarter. Assenagon Asset Management […]
M&T Bank Corp lowered its stake in argenx SE (NASDAQ:ARGX – Free Report) by 2.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,064 shares of the company’s stock after selling 86 shares during the quarter. M&T Bank Corp’s holdings in argenx were […]
argenx SE (NASDAQ:ARGX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have assigned a buy rating and one has issued a […]